nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—obesity—type 2 diabetes mellitus	0.296	1	CtDrD
Methamphetamine—Nateglinide—type 2 diabetes mellitus	0.292	1	CrCtD
Methamphetamine—ADRA2A—type 2 diabetes mellitus	0.0844	1	CbGaD
Methamphetamine—Lacosamide—Nateglinide—type 2 diabetes mellitus	0.0279	0.174	CrCrCtD
Methamphetamine—Aspartame—Nateglinide—type 2 diabetes mellitus	0.0279	0.174	CrCrCtD
Methamphetamine—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.02	0.229	CbGbCtD
Methamphetamine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.019	0.217	CbGbCtD
Methamphetamine—Phenacemide—Nateglinide—type 2 diabetes mellitus	0.0189	0.118	CrCrCtD
Methamphetamine—Dextroamphetamine—Nateglinide—type 2 diabetes mellitus	0.0184	0.115	CrCrCtD
Methamphetamine—Amphetamine—Nateglinide—type 2 diabetes mellitus	0.0184	0.115	CrCrCtD
Methamphetamine—Nateglinide—Ramipril—type 2 diabetes mellitus	0.0179	0.112	CrCrCtD
Methamphetamine—Aspartame—Ramipril—type 2 diabetes mellitus	0.017	0.106	CrCrCtD
Methamphetamine—L-Phenylalanine—Nateglinide—type 2 diabetes mellitus	0.014	0.0872	CrCrCtD
Methamphetamine—SLC22A3—Metformin—type 2 diabetes mellitus	0.0134	0.153	CbGbCtD
Methamphetamine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0132	0.151	CbGbCtD
Methamphetamine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0064	0.0732	CbGbCtD
Methamphetamine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00591	0.0675	CbGbCtD
Methamphetamine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00485	0.0555	CbGbCtD
Methamphetamine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00465	0.0532	CbGbCtD
Methamphetamine—Psychotic episode—Bromocriptine—type 2 diabetes mellitus	0.00246	0.0698	CcSEcCtD
Methamphetamine—Digestion impaired—Tolbutamide—type 2 diabetes mellitus	0.00125	0.0356	CcSEcCtD
Methamphetamine—Digestion impaired—Tolazamide—type 2 diabetes mellitus	0.00114	0.0324	CcSEcCtD
Methamphetamine—Digestion impaired—Chlorpropamide—type 2 diabetes mellitus	0.00114	0.0324	CcSEcCtD
Methamphetamine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00101	0.125	CbGeAlD
Methamphetamine—Cardio-respiratory arrest—Irbesartan—type 2 diabetes mellitus	0.000773	0.022	CcSEcCtD
Methamphetamine—Digestion impaired—Glipizide—type 2 diabetes mellitus	0.000757	0.0215	CcSEcCtD
Methamphetamine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.000679	0.0837	CbGeAlD
Methamphetamine—Digestion impaired—Glyburide—type 2 diabetes mellitus	0.000583	0.0165	CcSEcCtD
Methamphetamine—Digestion impaired—Gliclazide—type 2 diabetes mellitus	0.000523	0.0149	CcSEcCtD
Methamphetamine—SLC6A3—nerve—type 2 diabetes mellitus	0.000474	0.0584	CbGeAlD
Methamphetamine—MAOB—nerve—type 2 diabetes mellitus	0.000413	0.0509	CbGeAlD
Methamphetamine—SLC6A2—nerve—type 2 diabetes mellitus	0.000382	0.0471	CbGeAlD
Methamphetamine—MAOA—nerve—type 2 diabetes mellitus	0.000352	0.0434	CbGeAlD
Methamphetamine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000346	0.0427	CbGeAlD
Methamphetamine—Digestion impaired—Ramipril—type 2 diabetes mellitus	0.000333	0.00947	CcSEcCtD
Methamphetamine—Psychotic disorder—Bromocriptine—type 2 diabetes mellitus	0.000302	0.00858	CcSEcCtD
Methamphetamine—Tremor—Nateglinide—type 2 diabetes mellitus	0.00029	0.00822	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Miglitol—type 2 diabetes mellitus	0.000287	0.00816	CcSEcCtD
Methamphetamine—Constipation—Miglitol—type 2 diabetes mellitus	0.000285	0.00808	CcSEcCtD
Methamphetamine—Erectile dysfunction—Pioglitazone—type 2 diabetes mellitus	0.00028	0.00796	CcSEcCtD
Methamphetamine—Palpitations—Nateglinide—type 2 diabetes mellitus	0.000273	0.00775	CcSEcCtD
Methamphetamine—Phenformin—PRKAA1—type 2 diabetes mellitus	0.000273	0.179	CrCbGaD
Methamphetamine—Erectile dysfunction—Sitagliptin—type 2 diabetes mellitus	0.000272	0.00773	CcSEcCtD
Methamphetamine—Dyspepsia—Tolbutamide—type 2 diabetes mellitus	0.000263	0.00748	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Tolbutamide—type 2 diabetes mellitus	0.000258	0.00733	CcSEcCtD
Methamphetamine—Dyspepsia—Chlorpropamide—type 2 diabetes mellitus	0.00024	0.0068	CcSEcCtD
Methamphetamine—Dyspepsia—Tolazamide—type 2 diabetes mellitus	0.00024	0.0068	CcSEcCtD
Methamphetamine—Urticaria—Tolbutamide—type 2 diabetes mellitus	0.000238	0.00675	CcSEcCtD
Methamphetamine—Palpitations—Repaglinide—type 2 diabetes mellitus	0.000236	0.00671	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Chlorpropamide—type 2 diabetes mellitus	0.000235	0.00667	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Tolazamide—type 2 diabetes mellitus	0.000235	0.00667	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Linagliptin—type 2 diabetes mellitus	0.000233	0.0066	CcSEcCtD
Methamphetamine—Constipation—Linagliptin—type 2 diabetes mellitus	0.00023	0.00654	CcSEcCtD
Methamphetamine—Dyspepsia—Acarbose—type 2 diabetes mellitus	0.00023	0.00654	CcSEcCtD
Methamphetamine—Diarrhoea—Miglitol—type 2 diabetes mellitus	0.000228	0.00646	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Acarbose—type 2 diabetes mellitus	0.000226	0.00641	CcSEcCtD
Methamphetamine—Constipation—Acarbose—type 2 diabetes mellitus	0.000224	0.00635	CcSEcCtD
Methamphetamine—Dyspepsia—Nateglinide—type 2 diabetes mellitus	0.000222	0.0063	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Nateglinide—type 2 diabetes mellitus	0.000218	0.00618	CcSEcCtD
Methamphetamine—Urticaria—Tolazamide—type 2 diabetes mellitus	0.000216	0.00614	CcSEcCtD
Methamphetamine—Urticaria—Chlorpropamide—type 2 diabetes mellitus	0.000216	0.00614	CcSEcCtD
Methamphetamine—Urticaria—Linagliptin—type 2 diabetes mellitus	0.000214	0.00608	CcSEcCtD
Methamphetamine—Amphetamine—CARTPT—type 2 diabetes mellitus	0.000213	0.139	CrCbGaD
Methamphetamine—Urticaria—Acarbose—type 2 diabetes mellitus	0.000208	0.0059	CcSEcCtD
Methamphetamine—Tremor—Glipizide—type 2 diabetes mellitus	0.000207	0.00589	CcSEcCtD
Methamphetamine—Erectile dysfunction—Gliclazide—type 2 diabetes mellitus	0.000202	0.00574	CcSEcCtD
Methamphetamine—Urticaria—Nateglinide—type 2 diabetes mellitus	0.0002	0.00569	CcSEcCtD
Methamphetamine—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.000199	0.00564	CcSEcCtD
Methamphetamine—Tremor—Glimepiride—type 2 diabetes mellitus	0.000193	0.00549	CcSEcCtD
Methamphetamine—SLC18A2—adipose tissue—type 2 diabetes mellitus	0.000193	0.0238	CbGeAlD
Methamphetamine—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.000193	0.00547	CcSEcCtD
Methamphetamine—Dyspepsia—Repaglinide—type 2 diabetes mellitus	0.000192	0.00546	CcSEcCtD
Methamphetamine—Agitation—Glimepiride—type 2 diabetes mellitus	0.00019	0.00539	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.000188	0.00535	CcSEcCtD
Methamphetamine—Headache—Tolbutamide—type 2 diabetes mellitus	0.000187	0.00532	CcSEcCtD
Methamphetamine—Constipation—Repaglinide—type 2 diabetes mellitus	0.000187	0.0053	CcSEcCtD
Methamphetamine—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.000186	0.00529	CcSEcCtD
Methamphetamine—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.000186	0.00528	CcSEcCtD
Methamphetamine—Erectile dysfunction—Valsartan—type 2 diabetes mellitus	0.000186	0.00527	CcSEcCtD
Methamphetamine—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.000184	0.00523	CcSEcCtD
Methamphetamine—Palpitations—Glimepiride—type 2 diabetes mellitus	0.000183	0.00518	CcSEcCtD
Methamphetamine—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00018	0.00511	CcSEcCtD
Methamphetamine—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00018	0.00511	CcSEcCtD
Methamphetamine—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.000179	0.00508	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.000178	0.00506	CcSEcCtD
Methamphetamine—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.000176	0.00501	CcSEcCtD
Methamphetamine—Urticaria—Repaglinide—type 2 diabetes mellitus	0.000173	0.00492	CcSEcCtD
Methamphetamine—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.000173	0.0049	CcSEcCtD
Methamphetamine—Agitation—Bromocriptine—type 2 diabetes mellitus	0.000171	0.00486	CcSEcCtD
Methamphetamine—Phenelzine—AOC3—type 2 diabetes mellitus	0.000171	0.112	CrCbGaD
Methamphetamine—Headache—Chlorpropamide—type 2 diabetes mellitus	0.000171	0.00484	CcSEcCtD
Methamphetamine—Headache—Tolazamide—type 2 diabetes mellitus	0.000171	0.00484	CcSEcCtD
Methamphetamine—MAOA—islet of Langerhans—type 2 diabetes mellitus	0.000171	0.021	CbGeAlD
Methamphetamine—Headache—Linagliptin—type 2 diabetes mellitus	0.000169	0.00479	CcSEcCtD
Methamphetamine—Dizziness—Nateglinide—type 2 diabetes mellitus	0.000167	0.00473	CcSEcCtD
Methamphetamine—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000165	0.00467	CcSEcCtD
Methamphetamine—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.000164	0.00465	CcSEcCtD
Methamphetamine—Insomnia—Glipizide—type 2 diabetes mellitus	0.000163	0.00464	CcSEcCtD
Methamphetamine—MAOB—nephron tubule—type 2 diabetes mellitus	0.000161	0.0198	CbGeAlD
Methamphetamine—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.000161	0.00457	CcSEcCtD
Methamphetamine—Tremor—Glyburide—type 2 diabetes mellitus	0.00016	0.00453	CcSEcCtD
Methamphetamine—Dyspepsia—Glipizide—type 2 diabetes mellitus	0.000159	0.00451	CcSEcCtD
Methamphetamine—Insomnia—Pioglitazone—type 2 diabetes mellitus	0.000157	0.00444	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.000156	0.00443	CcSEcCtD
Methamphetamine—Constipation—Glipizide—type 2 diabetes mellitus	0.000154	0.00438	CcSEcCtD
Methamphetamine—SLC22A3—kidney—type 2 diabetes mellitus	0.000153	0.0188	CbGeAlD
Methamphetamine—Insomnia—Glimepiride—type 2 diabetes mellitus	0.000152	0.00433	CcSEcCtD
Methamphetamine—Insomnia—Sitagliptin—type 2 diabetes mellitus	0.000152	0.00431	CcSEcCtD
Methamphetamine—Erectile dysfunction—Losartan—type 2 diabetes mellitus	0.00015	0.00426	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.000149	0.00424	CcSEcCtD
Methamphetamine—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000149	0.00424	CcSEcCtD
Methamphetamine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.000148	0.00421	CcSEcCtD
Methamphetamine—Dyspepsia—Glimepiride—type 2 diabetes mellitus	0.000148	0.00421	CcSEcCtD
Methamphetamine—Dyspepsia—Sitagliptin—type 2 diabetes mellitus	0.000148	0.0042	CcSEcCtD
Methamphetamine—MAOA—retina—type 2 diabetes mellitus	0.000146	0.018	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000146	0.00413	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000145	0.00412	CcSEcCtD
Methamphetamine—MAOB—cardiovascular system—type 2 diabetes mellitus	0.000145	0.0178	CbGeAlD
Methamphetamine—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000144	0.00408	CcSEcCtD
Methamphetamine—Urticaria—Glipizide—type 2 diabetes mellitus	0.000143	0.00407	CcSEcCtD
Methamphetamine—Tremor—Gliclazide—type 2 diabetes mellitus	0.000143	0.00407	CcSEcCtD
Methamphetamine—MAOB—kidney—type 2 diabetes mellitus	0.000141	0.0174	CbGeAlD
Methamphetamine—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000141	0.00401	CcSEcCtD
Methamphetamine—Agitation—Gliclazide—type 2 diabetes mellitus	0.000141	0.00399	CcSEcCtD
Methamphetamine—SLC22A3—adipose tissue—type 2 diabetes mellitus	0.000138	0.017	CbGeAlD
Methamphetamine—MAOB—cortex of kidney—type 2 diabetes mellitus	0.000138	0.017	CbGeAlD
Methamphetamine—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000138	0.0039	CcSEcCtD
Methamphetamine—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000137	0.0039	CcSEcCtD
Methamphetamine—MAOA—nephron tubule—type 2 diabetes mellitus	0.000137	0.0169	CbGeAlD
Methamphetamine—Headache—Repaglinide—type 2 diabetes mellitus	0.000137	0.00388	CcSEcCtD
Methamphetamine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000136	0.00387	CcSEcCtD
Methamphetamine—SLC18A2—liver—type 2 diabetes mellitus	0.000136	0.0167	CbGeAlD
Methamphetamine—Palpitations—Gliclazide—type 2 diabetes mellitus	0.000135	0.00384	CcSEcCtD
Methamphetamine—SLC22A5—retina—type 2 diabetes mellitus	0.000134	0.0166	CbGeAlD
Methamphetamine—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000134	0.0038	CcSEcCtD
Methamphetamine—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000134	0.0038	CcSEcCtD
Methamphetamine—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000133	0.00379	CcSEcCtD
Methamphetamine—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000133	0.00378	CcSEcCtD
Methamphetamine—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000132	0.0163	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000131	0.00373	CcSEcCtD
Methamphetamine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000131	0.0161	CbGeAlD
Methamphetamine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.00013	0.00369	CcSEcCtD
Methamphetamine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000129	0.00367	CcSEcCtD
Methamphetamine—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.000129	0.00366	CcSEcCtD
Methamphetamine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000127	0.00362	CcSEcCtD
Methamphetamine—MAOB—adipose tissue—type 2 diabetes mellitus	0.000127	0.0157	CbGeAlD
Methamphetamine—SLC22A5—nephron tubule—type 2 diabetes mellitus	0.000126	0.0156	CbGeAlD
Methamphetamine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000124	0.00353	CcSEcCtD
Methamphetamine—Palpitations—Valsartan—type 2 diabetes mellitus	0.000124	0.00352	CcSEcCtD
Methamphetamine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000124	0.00351	CcSEcCtD
Methamphetamine—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000124	0.00351	CcSEcCtD
Methamphetamine—MAOA—cardiovascular system—type 2 diabetes mellitus	0.000123	0.0152	CbGeAlD
Methamphetamine—Palpitations—Orlistat—type 2 diabetes mellitus	0.000123	0.00348	CcSEcCtD
Methamphetamine—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000122	0.00347	CcSEcCtD
Methamphetamine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000122	0.00346	CcSEcCtD
Methamphetamine—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000121	0.00343	CcSEcCtD
Methamphetamine—MAOA—kidney—type 2 diabetes mellitus	0.000121	0.0149	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.00012	0.00341	CcSEcCtD
Methamphetamine—Tremor—Metformin—type 2 diabetes mellitus	0.00012	0.0034	CcSEcCtD
Methamphetamine—MAOA—pancreas—type 2 diabetes mellitus	0.00012	0.0148	CbGeAlD
Methamphetamine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000119	0.00339	CcSEcCtD
Methamphetamine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000118	0.00336	CcSEcCtD
Methamphetamine—MAOA—cortex of kidney—type 2 diabetes mellitus	0.000118	0.0145	CbGeAlD
Methamphetamine—ADRA2C—kidney—type 2 diabetes mellitus	0.000116	0.0143	CbGeAlD
Methamphetamine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000115	0.00327	CcSEcCtD
Methamphetamine—ADRA2C—pancreas—type 2 diabetes mellitus	0.000115	0.0142	CbGeAlD
Methamphetamine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000115	0.00326	CcSEcCtD
Methamphetamine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000114	0.00325	CcSEcCtD
Methamphetamine—Headache—Glipizide—type 2 diabetes mellitus	0.000113	0.00321	CcSEcCtD
Methamphetamine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000113	0.00321	CcSEcCtD
Methamphetamine—Palpitations—Metformin—type 2 diabetes mellitus	0.000113	0.00321	CcSEcCtD
Methamphetamine—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000113	0.0139	CbGeAlD
Methamphetamine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000113	0.0032	CcSEcCtD
Methamphetamine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000111	0.00316	CcSEcCtD
Methamphetamine—SLC22A5—kidney—type 2 diabetes mellitus	0.000111	0.0137	CbGeAlD
Methamphetamine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000111	0.00315	CcSEcCtD
Methamphetamine—Agitation—Irbesartan—type 2 diabetes mellitus	0.000111	0.00315	CcSEcCtD
Methamphetamine—Urticaria—Glyburide—type 2 diabetes mellitus	0.00011	0.00313	CcSEcCtD
Methamphetamine—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.00011	0.00312	CcSEcCtD
Methamphetamine—MAOA—adipose tissue—type 2 diabetes mellitus	0.000109	0.0134	CbGeAlD
Methamphetamine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000108	0.00308	CcSEcCtD
Methamphetamine—SLC22A5—cortex of kidney—type 2 diabetes mellitus	0.000108	0.0133	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000108	0.00306	CcSEcCtD
Methamphetamine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000107	0.00303	CcSEcCtD
Methamphetamine—Tremor—Losartan—type 2 diabetes mellitus	0.000106	0.00302	CcSEcCtD
Methamphetamine—Headache—Glimepiride—type 2 diabetes mellitus	0.000106	0.003	CcSEcCtD
Methamphetamine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000105	0.00299	CcSEcCtD
Methamphetamine—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000105	0.0129	CbGeAlD
Methamphetamine—Agitation—Losartan—type 2 diabetes mellitus	0.000104	0.00296	CcSEcCtD
Methamphetamine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000104	0.00295	CcSEcCtD
Methamphetamine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000104	0.00294	CcSEcCtD
Methamphetamine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000102	0.00291	CcSEcCtD
Methamphetamine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000102	0.00291	CcSEcCtD
Methamphetamine—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000101	0.00287	CcSEcCtD
Methamphetamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000101	0.00285	CcSEcCtD
Methamphetamine—Palpitations—Losartan—type 2 diabetes mellitus	0.0001	0.00285	CcSEcCtD
Methamphetamine—SLC22A5—adipose tissue—type 2 diabetes mellitus	0.0001	0.0123	CbGeAlD
Methamphetamine—Dyspepsia—Orlistat—type 2 diabetes mellitus	9.97e-05	0.00283	CcSEcCtD
Methamphetamine—Urticaria—Gliclazide—type 2 diabetes mellitus	9.92e-05	0.00281	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	9.9e-05	0.00281	CcSEcCtD
Methamphetamine—Constipation—Valsartan—type 2 diabetes mellitus	9.81e-05	0.00278	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	9.78e-05	0.00278	CcSEcCtD
Methamphetamine—SLC22A3—liver—type 2 diabetes mellitus	9.66e-05	0.0119	CbGeAlD
Methamphetamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	9.62e-05	0.00273	CcSEcCtD
Methamphetamine—Headache—Bromocriptine—type 2 diabetes mellitus	9.53e-05	0.0027	CcSEcCtD
Methamphetamine—Diarrhoea—Glyburide—type 2 diabetes mellitus	9.51e-05	0.0027	CcSEcCtD
Methamphetamine—ADRA2A—pancreas—type 2 diabetes mellitus	9.2e-05	0.0113	CbGeAlD
Methamphetamine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.2e-05	0.00261	CcSEcCtD
Methamphetamine—Dyspepsia—Metformin—type 2 diabetes mellitus	9.19e-05	0.00261	CcSEcCtD
Methamphetamine—Tremor—Ramipril—type 2 diabetes mellitus	9.13e-05	0.00259	CcSEcCtD
Methamphetamine—Urticaria—Valsartan—type 2 diabetes mellitus	9.11e-05	0.00259	CcSEcCtD
Methamphetamine—Nateglinide—ABCC8—type 2 diabetes mellitus	9.1e-05	0.0596	CrCbGaD
Methamphetamine—Tachycardia—Losartan—type 2 diabetes mellitus	9.05e-05	0.00257	CcSEcCtD
Methamphetamine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	9.02e-05	0.0111	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	9.02e-05	0.00256	CcSEcCtD
Methamphetamine—Urticaria—Orlistat—type 2 diabetes mellitus	9e-05	0.00256	CcSEcCtD
Methamphetamine—Agitation—Ramipril—type 2 diabetes mellitus	8.95e-05	0.00254	CcSEcCtD
Methamphetamine—MAOB—liver—type 2 diabetes mellitus	8.94e-05	0.011	CbGeAlD
Methamphetamine—Constipation—Metformin—type 2 diabetes mellitus	8.93e-05	0.00254	CcSEcCtD
Methamphetamine—Headache—Glyburide—type 2 diabetes mellitus	8.71e-05	0.00247	CcSEcCtD
Methamphetamine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	8.68e-05	0.00246	CcSEcCtD
Methamphetamine—Palpitations—Ramipril—type 2 diabetes mellitus	8.61e-05	0.00244	CcSEcCtD
Methamphetamine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	8.54e-05	0.00242	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	8.51e-05	0.00242	CcSEcCtD
Methamphetamine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	8.45e-05	0.0024	CcSEcCtD
Methamphetamine—Constipation—Irbesartan—type 2 diabetes mellitus	8.43e-05	0.00239	CcSEcCtD
Methamphetamine—Insomnia—Losartan—type 2 diabetes mellitus	8.39e-05	0.00238	CcSEcCtD
Methamphetamine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	8.35e-05	0.00237	CcSEcCtD
Methamphetamine—ADRA2A—adipose tissue—type 2 diabetes mellitus	8.34e-05	0.0103	CbGeAlD
Methamphetamine—Urticaria—Metformin—type 2 diabetes mellitus	8.3e-05	0.00236	CcSEcCtD
Methamphetamine—Dizziness—Gliclazide—type 2 diabetes mellitus	8.25e-05	0.00234	CcSEcCtD
Methamphetamine—Dyspepsia—Losartan—type 2 diabetes mellitus	8.16e-05	0.00232	CcSEcCtD
Methamphetamine—Constipation—Losartan—type 2 diabetes mellitus	7.93e-05	0.00225	CcSEcCtD
Methamphetamine—Diarrhoea—Valsartan—type 2 diabetes mellitus	7.85e-05	0.00223	CcSEcCtD
Methamphetamine—Urticaria—Irbesartan—type 2 diabetes mellitus	7.83e-05	0.00222	CcSEcCtD
Methamphetamine—Headache—Gliclazide—type 2 diabetes mellitus	7.82e-05	0.00222	CcSEcCtD
Methamphetamine—Tachycardia—Ramipril—type 2 diabetes mellitus	7.76e-05	0.0022	CcSEcCtD
Methamphetamine—Diarrhoea—Orlistat—type 2 diabetes mellitus	7.75e-05	0.0022	CcSEcCtD
Methamphetamine—Dexfenfluramine—HTR2C—type 2 diabetes mellitus	7.7e-05	0.0505	CrCbGaD
Methamphetamine—MAOA—liver—type 2 diabetes mellitus	7.63e-05	0.0094	CbGeAlD
Methamphetamine—Dizziness—Valsartan—type 2 diabetes mellitus	7.58e-05	0.00215	CcSEcCtD
Methamphetamine—Dizziness—Orlistat—type 2 diabetes mellitus	7.49e-05	0.00213	CcSEcCtD
Methamphetamine—Urticaria—Losartan—type 2 diabetes mellitus	7.37e-05	0.00209	CcSEcCtD
Methamphetamine—ADRA2C—liver—type 2 diabetes mellitus	7.33e-05	0.00904	CbGeAlD
Methamphetamine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.26e-05	0.00206	CcSEcCtD
Methamphetamine—Insomnia—Ramipril—type 2 diabetes mellitus	7.19e-05	0.00204	CcSEcCtD
Methamphetamine—Headache—Valsartan—type 2 diabetes mellitus	7.18e-05	0.00204	CcSEcCtD
Methamphetamine—CYP2D6—kidney—type 2 diabetes mellitus	7.17e-05	0.00884	CbGeAlD
Methamphetamine—Diarrhoea—Metformin—type 2 diabetes mellitus	7.15e-05	0.00203	CcSEcCtD
Methamphetamine—Headache—Orlistat—type 2 diabetes mellitus	7.1e-05	0.00202	CcSEcCtD
Methamphetamine—SLC22A5—liver—type 2 diabetes mellitus	7.02e-05	0.00866	CbGeAlD
Methamphetamine—Dyspepsia—Ramipril—type 2 diabetes mellitus	7e-05	0.00199	CcSEcCtD
Methamphetamine—Dizziness—Metformin—type 2 diabetes mellitus	6.91e-05	0.00196	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	6.87e-05	0.00195	CcSEcCtD
Methamphetamine—Hypersensitivity—Losartan—type 2 diabetes mellitus	6.83e-05	0.00194	CcSEcCtD
Methamphetamine—Constipation—Ramipril—type 2 diabetes mellitus	6.8e-05	0.00193	CcSEcCtD
Methamphetamine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.74e-05	0.00191	CcSEcCtD
Methamphetamine—Headache—Metformin—type 2 diabetes mellitus	6.54e-05	0.00186	CcSEcCtD
Methamphetamine—Dizziness—Irbesartan—type 2 diabetes mellitus	6.52e-05	0.00185	CcSEcCtD
Methamphetamine—Nateglinide—KCNJ11—type 2 diabetes mellitus	6.41e-05	0.042	CrCbGaD
Methamphetamine—Diarrhoea—Losartan—type 2 diabetes mellitus	6.35e-05	0.0018	CcSEcCtD
Methamphetamine—Urticaria—Ramipril—type 2 diabetes mellitus	6.32e-05	0.00179	CcSEcCtD
Methamphetamine—Headache—Irbesartan—type 2 diabetes mellitus	6.17e-05	0.00175	CcSEcCtD
Methamphetamine—Dizziness—Losartan—type 2 diabetes mellitus	6.13e-05	0.00174	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP2E1—type 2 diabetes mellitus	6.11e-05	0.04	CrCbGaD
Methamphetamine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	5.86e-05	0.00166	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP1A2—type 2 diabetes mellitus	5.81e-05	0.0381	CrCbGaD
Methamphetamine—Headache—Losartan—type 2 diabetes mellitus	5.81e-05	0.00165	CcSEcCtD
Methamphetamine—Diarrhoea—Ramipril—type 2 diabetes mellitus	5.44e-05	0.00154	CcSEcCtD
Methamphetamine—Dizziness—Ramipril—type 2 diabetes mellitus	5.26e-05	0.00149	CcSEcCtD
Methamphetamine—Tolazoline—ADRA2A—type 2 diabetes mellitus	5.17e-05	0.0339	CrCbGaD
Methamphetamine—Headache—Ramipril—type 2 diabetes mellitus	4.98e-05	0.00141	CcSEcCtD
Methamphetamine—CYP2D6—liver—type 2 diabetes mellitus	4.53e-05	0.00559	CbGeAlD
Methamphetamine—Phenylpropanolamine—ADRA2A—type 2 diabetes mellitus	4.52e-05	0.0296	CrCbGaD
Methamphetamine—Pseudoephedrine—ADRA2A—type 2 diabetes mellitus	3.82e-05	0.025	CrCbGaD
Methamphetamine—Pseudoephedrine—TNF—type 2 diabetes mellitus	3.62e-05	0.0237	CrCbGaD
Methamphetamine—Nateglinide—PPARG—type 2 diabetes mellitus	3.55e-05	0.0233	CrCbGaD
Methamphetamine—Phenylpropanolamine—CYP1A2—type 2 diabetes mellitus	3.14e-05	0.0206	CrCbGaD
Methamphetamine—Benzphetamine—ADRA2A—type 2 diabetes mellitus	2.85e-05	0.0187	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP2E1—type 2 diabetes mellitus	2.84e-05	0.0186	CrCbGaD
Methamphetamine—Phentermine—CYP1A2—type 2 diabetes mellitus	2.8e-05	0.0183	CrCbGaD
Methamphetamine—Selegiline—CYP2E1—type 2 diabetes mellitus	2.72e-05	0.0178	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP1A2—type 2 diabetes mellitus	2.7e-05	0.0177	CrCbGaD
Methamphetamine—Selegiline—CYP1A2—type 2 diabetes mellitus	2.59e-05	0.017	CrCbGaD
Methamphetamine—Phenelzine—CYP2E1—type 2 diabetes mellitus	2.4e-05	0.0157	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP3A4—type 2 diabetes mellitus	1.79e-05	0.0117	CrCbGaD
Methamphetamine—Selegiline—CYP3A4—type 2 diabetes mellitus	1.71e-05	0.0112	CrCbGaD
Methamphetamine—Nateglinide—CYP3A4—type 2 diabetes mellitus	1.53e-05	0.01	CrCbGaD
Methamphetamine—Phenelzine—CYP3A4—type 2 diabetes mellitus	1.51e-05	0.00989	CrCbGaD
Methamphetamine—Nateglinide—ALB—type 2 diabetes mellitus	1.34e-05	0.00876	CrCbGaD
Methamphetamine—Benzphetamine—CYP3A4—type 2 diabetes mellitus	1.31e-05	0.00858	CrCbGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.67e-06	4.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.67e-06	4.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.66e-06	4.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.66e-06	4.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.66e-06	4.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.65e-06	4.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.63e-06	4.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CD36—type 2 diabetes mellitus	1.63e-06	4.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.62e-06	4.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.62e-06	4.71e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTGS2—type 2 diabetes mellitus	1.62e-06	4.69e-05	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.61e-06	4.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPP2CA—type 2 diabetes mellitus	1.61e-06	4.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.61e-06	4.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.6e-06	4.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.6e-06	4.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SRC—type 2 diabetes mellitus	1.6e-06	4.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.59e-06	4.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.58e-06	4.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.58e-06	4.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.56e-06	4.52e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	1.56e-06	4.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—type 2 diabetes mellitus	1.56e-06	4.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AVP—type 2 diabetes mellitus	1.56e-06	4.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.56e-06	4.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.55e-06	4.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTHFR—type 2 diabetes mellitus	1.55e-06	4.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.54e-06	4.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LPL—type 2 diabetes mellitus	1.54e-06	4.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.53e-06	4.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GNB3—type 2 diabetes mellitus	1.53e-06	4.44e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	1.53e-06	4.43e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	1.53e-06	4.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.53e-06	4.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HMOX1—type 2 diabetes mellitus	1.52e-06	4.42e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PPARG—type 2 diabetes mellitus	1.52e-06	4.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARA—type 2 diabetes mellitus	1.52e-06	4.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.51e-06	4.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.5e-06	4.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.5e-06	4.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CAT—type 2 diabetes mellitus	1.5e-06	4.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOB—type 2 diabetes mellitus	1.5e-06	4.36e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	1.5e-06	4.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.5e-06	4.34e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—INS—type 2 diabetes mellitus	1.49e-06	4.33e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	1.49e-06	4.32e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	1.49e-06	4.32e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	1.49e-06	4.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.49e-06	4.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.49e-06	4.31e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	1.48e-06	4.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.48e-06	4.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AGT—type 2 diabetes mellitus	1.47e-06	4.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.46e-06	4.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	1.46e-06	4.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.46e-06	4.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	1.45e-06	4.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CALM1—type 2 diabetes mellitus	1.44e-06	4.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.44e-06	4.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	1.44e-06	4.17e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	1.44e-06	4.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	1.44e-06	4.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	1.43e-06	4.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	1.42e-06	4.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	1.42e-06	4.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.42e-06	4.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.41e-06	4.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	1.39e-06	4.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.39e-06	4.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	1.38e-06	4.01e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ALB—type 2 diabetes mellitus	1.37e-06	3.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.37e-06	3.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	1.37e-06	3.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.36e-06	3.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	1.36e-06	3.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.35e-06	3.9e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	1.34e-06	3.87e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	1.34e-06	3.87e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	1.34e-06	3.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	1.32e-06	3.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.32e-06	3.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.32e-06	3.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.32e-06	3.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	1.31e-06	3.81e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	1.31e-06	3.8e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3R1—type 2 diabetes mellitus	1.31e-06	3.8e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NOS3—type 2 diabetes mellitus	1.31e-06	3.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	1.31e-06	3.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	1.31e-06	3.79e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	1.3e-06	3.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.29e-06	3.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.29e-06	3.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	1.29e-06	3.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	1.29e-06	3.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	1.29e-06	3.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.28e-06	3.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.27e-06	3.69e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	1.27e-06	3.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.26e-06	3.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.26e-06	3.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.26e-06	3.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	1.26e-06	3.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	1.25e-06	3.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.25e-06	3.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.24e-06	3.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.23e-06	3.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	1.23e-06	3.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.23e-06	3.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	1.23e-06	3.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	1.23e-06	3.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	1.22e-06	3.54e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	1.22e-06	3.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	1.22e-06	3.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.22e-06	3.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.21e-06	3.52e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	1.21e-06	3.5e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	1.21e-06	3.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.21e-06	3.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	1.2e-06	3.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	1.2e-06	3.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.2e-06	3.48e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—type 2 diabetes mellitus	1.2e-06	3.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	1.19e-06	3.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.19e-06	3.45e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	1.18e-06	3.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	1.17e-06	3.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	1.17e-06	3.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	1.17e-06	3.38e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	1.16e-06	3.36e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	1.16e-06	3.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	1.16e-06	3.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.15e-06	3.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.14e-06	3.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.13e-06	3.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	1.13e-06	3.27e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	1.1e-06	3.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.09e-06	3.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.08e-06	3.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	1.08e-06	3.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	1.08e-06	3.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.07e-06	3.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.07e-06	3.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.06e-06	3.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.06e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.06e-06	3.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.05e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	1.03e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	1.02e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.01e-06	2.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.01e-06	2.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.99e-07	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	9.99e-07	2.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	9.98e-07	2.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	9.98e-07	2.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	9.98e-07	2.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.94e-07	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.94e-07	2.88e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	9.94e-07	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	9.93e-07	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	9.89e-07	2.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	9.86e-07	2.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.81e-07	2.84e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	9.8e-07	2.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	9.77e-07	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	9.77e-07	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.66e-07	2.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.65e-07	2.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.65e-07	2.8e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—type 2 diabetes mellitus	9.6e-07	2.78e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	9.52e-07	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	9.44e-07	2.74e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	9.26e-07	2.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	9.22e-07	2.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	9.15e-07	2.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	9.09e-07	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	9.08e-07	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.01e-07	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.01e-07	2.61e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	8.9e-07	2.58e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	8.87e-07	2.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	8.76e-07	2.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	8.76e-07	2.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.72e-07	2.53e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	8.63e-07	2.5e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	8.53e-07	2.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	8.49e-07	2.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	8.35e-07	2.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	8.27e-07	2.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.22e-07	2.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.19e-07	2.38e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	8.18e-07	2.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.14e-07	2.36e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—type 2 diabetes mellitus	8.12e-07	2.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.08e-07	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.07e-07	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.04e-07	2.33e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	8.03e-07	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	8.01e-07	2.32e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	7.77e-07	2.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.74e-07	2.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.72e-07	2.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.67e-07	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.66e-07	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.65e-07	2.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	7.64e-07	2.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	7.62e-07	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.6e-07	2.2e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	7.53e-07	2.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.51e-07	2.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.32e-07	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.32e-07	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.23e-07	2.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.16e-07	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	7.14e-07	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.01e-07	2.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.95e-07	2.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	6.89e-07	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	6.67e-07	1.93e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	6.63e-07	1.92e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	6.51e-07	1.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.49e-07	1.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.38e-07	1.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.27e-07	1.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.26e-07	1.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.22e-07	1.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.18e-07	1.79e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—type 2 diabetes mellitus	6.03e-07	1.75e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	5.97e-07	1.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.96e-07	1.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.87e-07	1.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.84e-07	1.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.81e-07	1.68e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	5.71e-07	1.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	5.71e-07	1.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.7e-07	1.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	5.42e-07	1.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.28e-07	1.53e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	5.22e-07	1.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	4.96e-07	1.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.84e-07	1.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	4.81e-07	1.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.75e-07	1.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	4.49e-07	1.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.44e-07	1.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.14e-07	1.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	4.03e-07	1.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.65e-07	1.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.37e-07	9.76e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	2.62e-07	7.6e-06	CbGpPWpGaD
